Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia
about
Investigational drugs to treat methicillin-resistant Staphylococcus aureusWhere does a Staphylococcus aureus vaccine stand?A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposureBad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of AmericaProgress towards recombinant anti-infective antibodies.Inhibition of toxic shock by human monoclonal antibodies against staphylococcal enterotoxin B.Novel targeted immunotherapy approaches for staphylococcal infection.Preventing Staphylococcus aureus sepsis through the inhibition of its agglutination in blood.Progress in the development of effective vaccines to prevent selected gram-positive bacterial infections.Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus.Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters.Vaccine protection of leukopenic mice against Staphylococcus aureus bloodstream infectionMechanisms of NDV-3 vaccine efficacy in MRSA skin versus invasive infection.Protein A suppresses immune responses during Staphylococcus aureus bloodstream infection in guinea pigs.Active immunization with an octa-valent Staphylococcus aureus antigen mixture in models of S. aureus bacteremia and skin infection in miceAn evaluation of the emerging vaccines and immunotherapy against staphylococcal pneumonia in children.Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance?Immunization with Staphylococcus aureus iron regulated surface determinant B (IsdB) confers protection via Th17/IL17 pathway in a murine sepsis modelPhase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremiaInnate Immune Signaling Activated by MDR Bacteria in the AirwayEpidemiology and outcome of major postoperative infections following cardiac surgery: risk factors and impact of pathogen type.Exploring Staphylococcus aureus pathways to disease for vaccine development.Preclinical Efficacy of Clumping Factor A in Prevention of Staphylococcus aureus Infection.Antibody-Based Biologics and Their Promise to Combat Staphylococcus aureus Infections.Immunopathogenesis of Staphylococcus aureus pulmonary infection.Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Global antibody response to Staphylococcus aureus live-cell vaccinationMonoclonal antibodies for prophylaxis and therapy of infectious diseases.Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus DiseaseManagement of catheter-related infection.Successful selection of an infection-protective anti-Staphylococcus aureus monoclonal antibody and its protective activity in murine infection modelsLessons from the Crystal Structure of the S. aureus Surface Protein Clumping Factor A in Complex With Tefibazumab, an Inhibiting Monoclonal Antibody.Invasive community-associated MRSA infections: epidemiology and antimicrobial management.Immune proteomics of Staphylococcus aureus.Advances in the diagnosis and management of pediatric osteomyelitis.Diabetic foot infections: microbiological aspects, current and future antibiotic therapy focusing on methicillin-resistant Staphylococcus aureus.Challenges for a universal Staphylococcus aureus vaccine.Staphylococcus aureus Colonization: Modulation of Host Immune Response and Impact on Human Vaccine Design.Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.
P2860
Q26780246-E4A135D1-9D93-461C-86B6-31F9650D5A9EQ26828726-0D446D8D-E053-4A6A-B7BA-4E53A2E3F007Q28714292-28C9BD4F-45DB-4CF6-B933-5B16CBA00F1EQ29616084-D96D6343-E850-4D02-90A5-B4FE10050E23Q33568256-05348C40-9D4E-43CF-BD4B-CF0B7691E9FAQ33719201-43DAEDEA-4C55-4C7B-8310-F4546EB2BC4DQ33910565-BC3C79F2-C286-462D-A665-59D1A110021DQ34058113-43F45BBF-B2A3-4DD5-9A8B-C94B0815B06BQ34112608-511BFBEF-6186-4B5B-9E58-F515176185B6Q34250054-141B011E-7302-43BF-9A5C-9A2A42C8BAC4Q34522708-AAA3D2B7-BB6B-4B3E-A4CC-D00C506B5CE1Q34596203-EBF80962-1378-446B-BBFB-6D8ED6BB420BQ34792962-38B65B52-92D5-4EE7-B5C7-8B73D6F061A2Q35038206-200DF2E3-4913-487D-B80D-1EB33A7F008CQ35116935-34B31A26-4BF1-45A3-8018-2D9361B7A2CFQ35618211-E1F848E4-C346-4876-8400-9D792BE28FC1Q35736907-0D76ACD4-B030-4B83-B695-9068FED42AC5Q36184397-A0114F73-84C3-4781-B5B7-BAF18251FFE7Q36313264-1C0E9929-6BE1-4C56-A35F-50D934E14706Q36422470-FDE80008-5261-4C6A-B329-7EB21DE8ECD2Q36503755-A7604E63-2BE2-4669-AC4B-F6AC6AF701DFQ36516970-E798BC71-17AA-4959-BB58-27092C33ECC4Q36548288-9DEEB676-C3BB-46E5-9EF2-240E8B8E15B9Q36609408-4AD40EF3-9A9C-4405-ADF1-3F4E5D01E5F3Q36623309-17397870-CFBF-46E3-8C98-4607BA5A9881Q36718474-7FB36D0F-1E65-4364-AD72-1FB5E2C94451Q36758570-9AE407FB-ED8F-4914-A2F7-C1ED35E08BE1Q36824281-ACD422A0-EE3B-4A87-A1C7-93CEB28B359FQ36989900-F6704649-D8CF-44E2-8811-3F4F05F98566Q37075941-E5642319-F5ED-4F4A-A6C7-4FD0645D6B90Q37077615-D5FEF23E-1A3C-4CF2-9575-B3976473B78BQ37269558-5B28BDA5-B916-4982-B1F1-D5912291E09EQ37605209-36D34F96-8254-48B1-829D-2F1F3EFA67F5Q37800939-6B069B02-9500-4617-851D-DB498A1DAF9FQ37895214-6F16DD54-7417-4DE3-B59F-AB82687820A0Q37905654-BFBEF949-B7C8-471A-8E84-CE792EA9F447Q37924980-04B27C2F-6220-4483-9788-9DDD9F3E21C4Q37987099-A9564BA2-4663-456E-A4D5-D2D7D4D2E974Q38177271-5B1DAA2F-EEAE-4F56-8A63-CB170023F2F2Q38674449-6E9C355F-3CB9-417E-95D8-66C5FC65CC59
P2860
Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@ast
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@en
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@nl
type
label
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@ast
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@en
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@nl
prefLabel
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@ast
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@en
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@nl
P2093
P2860
P356
P1476
Phase II, randomized, double-b ...... aphylococcus aureus bacteremia
@en
P2093
Christine J Kubin
Eric Wenzel
G Ralph Corey
J John Weems
James P Steinberg
John W Baddley
Joseph F John
Joseph M Patti
Lisa Winston
Michele Texter
P2860
P304
P356
10.1128/AAC.00096-06
P407
P577
2006-08-01T00:00:00Z